Phase 2 N=56 Buffered Lidocaine for Loop Electrosurgical Excision Procedures (LEEPs)
Uterine Cervical Dysplasia
Primary: Injection Pain Score (Mean) — 25; 19 units on a scale — p=.13
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)
Hepatitis C
Primary: Change From Baseline in log10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels — -2.02; 0.16; -3.43; -2.71 log10 IU/mL
Phase 1 N=30 Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects
Healthy
Primary: Empa 25mg: Mean QTcN Change From Baseline Between 1 and 4 Hours After Dosing — 3.68; 4.27 ms
Phase 2 N=100 Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
Gout
Primary: Serum Uric Acid — -16.0; -9.9; -9.5 percent change
Phase 2 N=124 Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism
Secondary Hypogonadism
Primary: Change in Total Morning Testosterone — -16.9; 253.7; 258.5; 197.3 ng/dL
Phase 4 N=21 Zoledronic Acid Administration in Acute Spinal Cord Injury
Disuse Osteoporosis
Primary: Bone Mineral Density (BMD) at the Distal Femur and Proximal Tibia at Baseline and Month 12. — 1.102; 1.134; 0.898; 1.038 g/cm2
Phase 3 N=90 Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria
Phenylketonuria
Primary: Percentage of Participants With Response to Kuvan® (Sapropterin Dihydrochloride) Treatment — 33.3 percentage of participants
N/A N=228 Improving Patient Satisfaction Improving Patient Satisfaction
Satisfaction · Trauma
Primary: Patient Satisfaction as Measured by Giving an "Excellent" Score on a 5-point Rating — 25; 22 participants
Phase 2 N=43 Family-Focused, Stress-Reduction Program to Improve the Health Care of Urban Children With Asthma
Asthma
Primary: Mean Score on the Family Asthma Management System Scale (FAMSS) — 4.9; 4.1 units on a scale — p=0.23
Phase 2 N=58 Determination of the Lowest, Safe and Effective Dose of Proellex
Amenorrhea
Primary: Induction Amenorrhea — 2; 9; 6; 8 participants
Phase 1 N=25 A Safety and Pharmacokinetic Study of Proellex®
Healthy
Primary: Cmax Post Final Dose — 1944; 3807; 2293; 2777 ng/mL
Phase 1 N=18 Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin
Healthy
Primary: Empa: Area Under the Curve 0 to Infinity (AUC0-∞) — 5571.70; 5685.69 nmol*h/L
N/A N=156 Retrospective Transverse Observational Study Of Previous Study (Initial Protocol, B1811030)
Survival Status at Day 30 After the Last Intake
Primary: Percentage of Participants With Survival at 30 Days After Last Dose of Tigecycline — 80.60 percentage of participants
Phase 2 N=272 Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
Acellular Pertussis · Hepatitis B · Haemophilus Influenzae Type b
Primary: Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies — 81; 82; 90; 81 Participants
Phase 2 N=54 A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Colorectal Cancer
Primary: Percentage of Participants Achieving Overall Disease Control (ODC) — 87 percentage of participants